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ABSTRACT
Objective: In Taiwan, the carrier rate of hepatitis B surface
antigen is 15% to 20%, one of the highest in the world.
Among chronic hepatitis B (CHB) patients, hepatitis B e
antigen (HBeAg)-negative accounts for approximately 40%
to 50% of these patients. A recent study found that peginter-
feron alfa-2a (40 KD) is more effective than lamivudine in
treating HBeAg-negative CHB, but its cost-effectiveness
has not been evaluated. Our objective is to evaluate the
incremental cost-effectiveness of 48 weeks of peginterferon
alfa-2a compared to 48 weeks of lamivudine, from the per-
spective of the Taiwan Bureau of National Health Insurance.
Methods: A Markov model was used to simulate the natural
history of HBeAg-negative CHB in a cohort of 40-year-old
patients. Efﬁcacy, disease progression, economic, and quality-
of-life data were derived from published literature and a
survey of clinical experts in Taiwan. Life expectancy, quality-
adjusted life expectancy, lifetime costs in New Taiwan
Dollars (NTD) (1 USD = 31.96 NTD), and incremental cost-
effectiveness ratios (ICERs) were calculated.
Results: The gain in quality-adjusted life-years (QALYs) for
48 weeks of peginterferon alfa-2a compared to 48 weeks of
lamivudine was 0.45 at an additional cost of 157,000 NTD
(4900 USD), resulting in an ICER of 347,000 NTD (10,900
USD) per QALY gained. The 95% central range for the ICER
from a probabilistic sensitivity analysis was 228,000–
566,000 NTD (7100–17,700 USD).
Conclusions: In HBeAg-negative CHB, 48 weeks of treat-
ment with peginterferon alfa-2a compared to 48 weeks of
lamivudine appears to offer life expectancy and quality-of-
life improvements at an acceptable cost-effectiveness ratio.
Keywords: cost-effectiveness, hepatitis B, lamivudine,
peginterferon, Taiwan.
Background
Chronic hepatitis B (CHB) infection is an important
public health problem worldwide, with about two
billion people having experienced acute infection, of
which 350 million have developed chronic hepatitis B
virus (HBV) infection. Approximately 75% of the
infected persons are in Asia. In Taiwan, the carrier rate
of hepatitis B surface antigen (HBsAg) is as high as
15% to 20%, one of the highest in the world [1]. HBV
infection is usually acquired from perinatal transmis-
sion [2]. In Taiwan, heterosexual contact is also con-
sidered an important cause of hepatitis B transmission
for susceptible adults [1].
Chronic HBV infection is characterized by the per-
sistence of HBsAg and serum HBV-DNA levels detect-
able for more than 6 months. Among patients with
active viral replication, cirrhosis will develop in 15% to
20% of patients within 5 years [3]. For patients with
cirrhosis, the disease may progress, and the incidence of
hepatocellular carcinoma (HCC) is greatly increased
(70–90% of HCC patients have cirrhosis) [3]. In a
Taiwanese case–control study, the relative risk of devel-
oping HCC, compared to non-carriers, was 64.7 for
carriers of HBsAg and hepatitis B e antigen (HBeAg)
and 17.9 for carriers of HBsAg only [4].
According to the top 10 causes of death published
by the Taiwanese Department of Health, chronic hepa-
titis disease as well as liver cirrhosis caused 5185
deaths (mortality rate: 22.98 per 100,000 population)
in 2003, and ranked in the sixth position of the top 10
causes of death [5]. Liver cancer led to 7010 deaths
(mortality rate: 31.07 per 100,000 population) in
2003 and was the leading cause of cancer deaths in
Taiwan [5]. The economic burden of HBV infection is
also substantial because of the high morbidity associ-
ated with decompensated cirrhosis and HCC. Accord-
ing to the Bureau of National Health Insurance
(BNHI), approximately 5.57 billion New Taiwan
Dollars (NTD) (i.e., 173.3 million USD) was spent on
the medical care of patients with chronic hepatitis,
cirrhosis, and HCC in 2002 [6].
In some patients, HBeAg seroconversion is accom-
panied by the selection of HBV variants that are
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unable to produce HBeAg. A proportion of these
HBeAg-negative (mutant type CHB) patients may later
develop higher levels of HBV replication and progress
to HBeAg-negative chronic hepatitis. Among CHB
patients, HBeAg-negative accounts for approximately
40% to 50% of these patients [1,7,8].
The treatments currently approved and reimbursed
by the Taiwan BNHI for patients with HBeAg-negative
CHB are interferon alfa and lamivudine. Nevertheless,
the majority of the patients treated in Taiwan are
treated with lamivudine, making lamivudine the stan-
dard of care in Taiwan. Recently, peginterferon alfa-2a
(40 KD) also was approved in Taiwan based on a
phase III randomized controlled international clinical
trial published by Marcellin et al. evaluating the efﬁ-
cacy and safety of peginterferon alfa-2a (40 KD) com-
bined with placebo or lamivudine versus lamivudine
alone in HBeAg-negative patients with CHB [9].
A total of 552 patients were enrolled in the study,
61.8% of whom were Asian. Patients were treated
for 48 weeks with a 24-week treatment-free follow-
up period. Signiﬁcantly more patients treated with
peginterferon alfa-2a (with or without lamivudine)
achieved a sustained response at end of follow-up
(6 months post treatment) than patients treated with
lamivudine monotherapy with respect to the copri-
mary end points of ALT normalization (59% and 60%
vs. 44%, respectively; P = 0.003) and HBV-DNA sup-
pression (HBV DNA < 20,000 copies/ml) (43% and
44% vs. 29%, respectively; P = 0.005) at week 72. The
combined end point of ALT normalization and HBV-
DNA suppression at the end of follow-up was achieved
in 36%, 38%, and 23% (P = 0.004) of patients receiv-
ing peginterferon alfa-2a, peginterferon alfa-2a plus
lamivudine, and lamivudine, respectively. Five patients
(3%) treated with peginterferon alfa-2a monotherapy,
three (2%) treated with peginterferon alfa-2a plus
lamivudine, and none treated with lamivudine showed
HBsAg seroconversion at the end of follow-up [9].
Although peginterferon alfa-2a has improved clini-
cal outcomes compared to lamivudine at deﬁned treat-
ment duration, the cost of 48 weeks of therapy is
higher by 172,704 NTD. Thus, the question for
health-care payers arises: Are the clinical beneﬁts
worth the additional cost? The objectives of this analy-
sis were to model the long-term clinical and economic
outcomes associated with peginterferon alfa-2a versus
lamivudine treatment in HBeAg-negative CHB based
on the results of the randomized clinical trial data, and
to evaluate the relative cost-effectiveness of these two
therapies from the Taiwan BNHI perspective.
Methods
Model Description
A Markov model of HBeAg-negative disease was uti-
lized to forecast the long-term clinical and economic
effects of peginterferon alfa-2a versus lamivudine for
the treatment of HBeAg-negative CHB. The course of
HBeAg-negative disease was represented as a sequence
of transitions between mutually exclusive health states,
each of which was deﬁned by a patient’s clinical condi-
tion. Associatedwith the health states were correspond-
ing quality-of-life values and costs. The health states
were deﬁned to reﬂect CHB (starting health state),
response, compensated cirrhosis, decompensated cir-
rhosis, HCC, liver transplantation, and death (Fig. 1).
The model linked combined response rate (HBV-DNA
suppression to HBV DNA < 20,000 copies/ml, and
ALT normalization) at the end of follow-up (24 weeks
post treatment) measured in Marcellin et al.’s phase III
clinical study [9] to ﬁnal outcomes, life-years gained,
and quality-adjusted life-years (QALYs) gained [10]. A
hypothetical cohort of patients with a mean age of
40 years was used in the model, based on the charac-
teristics of HBeAg-negative CHB patients in the clinical
trial [9]. Overall, the population used in the modeled
evaluation is expected to be similar to the target popu-
lation in Taiwan. This was conﬁrmed by a local Taiwan-
ese study performed in patients with HBeAg-negative
CHB [11] and by local expert hepatologists.
The time horizon of the analysis extended over
a patient’s lifetime, and was divided into equal
Figure 1 Structure of disease simulation
model. Patients could move between health
states in yearly cycles; all patients could experi-
ence non-HBV-related mortality. CHB, chronic
hepatitis B; HBeAg, hepatitis B e antigen.
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increments of time (in this case, 1 year each), known
as Markov cycles, during which patients “transition”
from one health state to another [10]. In each 1-year
cycle, patients with active CHB were at risk of devel-
oping compensated cirrhosis or HCC. Patients in the
response state could spontaneously return to the
CHB state, and had a small risk of progressing to
compensated cirrhosis. Patients in the CHB state
could also spontaneously move to the response state,
although at a low rate. Patients who developed com-
pensated cirrhosis faced a future risk of developing
HCC or decompensated cirrhosis. Patients who
developed decompensated cirrhosis could develop
HCC or receive a liver transplantation. Finally,
patients with HCC probably need liver transplanta-
tion and have an increased risk disease-related mor-
tality. The liver transplantation health state was
represented by two distinct health states: 1) the year
in which the transplantation was received; and 2) the
second and subsequent years after transplantation.
For each 1-year cycle, patients faced competing mor-
tality risks from complications related to CHB or
other causes. Patients who achieved response were
assumed to face the same mortality risk as healthy
individuals. Age-speciﬁc standard life tables from
2002 were used to reﬂect the background risk of
death from causes other than CHB in the general
population [12]. The probability of YMDD mutation
caused by lamivudine treatment and use of adefovir
salvage therapy was not included in our analysis,
as adefovir is not currently reimbursed by the BNHI.
We also opted to be conservative and not take into
account the occurrence of HBsAg seroconversion
with peginterferon alfa-2a therapy seen in Marcellin
et al.’s study [9].
Treatment Response and Disease Progression Estimates
The annual probabilities of moving between health
states in the model were estimated based on a thor-
ough review of the clinical literature, particularly
publications based on Taiwanese patients, using
MEDLINE (search 1950 to November 2004). In addi-
tion, we reviewed professional treatment guidelines
and consensus statements, previously published eco-
nomic models of CHB treatment, and input from a
panel of eight hepatologists in Taiwan (Table 1)
[5,7,9,11,13–24]. We used data from local Taiwanese
publications whenever these data were available. In
addition, a questionnaire compiled of transition rates
reported in the medical literature was administered to
the panel of eight expert hepatologists to ensure that
the most appropriate estimates for Taiwanese patients
with HBeAg-negative CHB were used in the model.
As discussed above, the estimates for sustained
(6 months post treatment) combined treatment
response (ALT normalization and HBV-DNA suppres-
sion) were derived from the randomized clinical trial
comparing 48 weeks of peginterferon alfa-2a treat-
ment to 48 weeks of lamivudine treatment [9]. The
response rate for peginterferon alfa-2a was 36% for
both the end of treatment (week 48) and the end of
follow-up (week 72), and for lamivudine was 69% at
the end of treatment and 23% at the end of follow-up
(67% relapse). Nevertheless, additional treatment
relapse may occur beyond that observed in the trial at
6 months follow-up. There are few data for lamivu-
Table 1 Annual probabilities of transition between health states





Combined response CHB, 6th month to 12th month post lamivudine treatment 50 (40–60) [20]
CHB, 6th month to 12th month post peginterferon alfa-2a treatment 25 (15–35) [9,11]
CHB, spontaneous relapse 6 (3–10) [22,24]
Compensated cirrhosis 1.3 (1–2) [13]
CHB Compensated cirrhosis 9 (6–12) [7]
Hepatocellular carcinoma 0.83 (0.5–2) [14]
Spontaneous response 1.6 (1–3) [11,24]
Compensated cirrhosis Decompensated cirrhosis 5 (2.3–5.6) [21]
Hepatocellular carcinoma 7.1 (2.8–7.1) [15]
Death 5.1 (3.4–5.1) [16]
Decompensated cirrhosis Hepatocellular carcinoma 2.5 (2–8) [21]
Liver transplantation 1.4 (0.05–3.1) [5,17]
Death 39 (23.5–40) [21]
Hepatocellular carcinoma Liver transplantation 0.08 (0.02–0.08) [18]
Death 37.2 (37–56) [23]
Liver transplantation Post liver transplantation 85 (79–90) [19]
Death 15 (10–21) [19]
Post-liver transplantation Death, second year and beyond 1.5 (1–5.7) [19]
Annual transition probabilities do not add to 1 because there is an annual probability to death from non-CHB-related causes and a residual probability of remaining in the same
health state that are not listed here.
CHB, chronic hepatitis B.
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dine on relapse beyond 6 months, but several studies
indicate that the 1–2 years post-treatment combined
response rate is 11% to 20% [20,25,26]. We consid-
ered the studies by Santantonio et al. and Tassopoulos
et al. to be most relevant for lamivudine, as they
reported combined treatment response data at the end
of treatment and the end of follow-up [20,25,26].
Santantonio et al. reported 83% relapse at 1 year
follow-up and Tassopoulos et al. reported 83% relapse
at 6 months follow-up. Based on these data, we
assumed conservatively that the 1-year total relapse
rate was 80%; to reproduce this value in the model,
approximately 50% of the 23% of lamivudine patients
with response at 6 months follow-up would need to
relapse in addition to the 67% who relapsed in the ﬁrst
6 months of follow-up (67% + 0.5 ¥ 23% = 78.5%).
We thus assumed 50% of lamivudine patients who had
combined response at 6 months relapsed by the end of
year 1.
There are no data on long-term combined response
for peginterferon alfa-2a, and few data for interferon
alfa. One study suggested an additional 50% of
interferon-treated patients relapse between 6 months
and 32 months post treatment [11]. Nevertheless,
given that there was no relapse at 6 months post treat-
ment in the peginterferon alfa-2a arm in Marcellin
et al.’s clinical study [9], we assumed an additional
25% relapse with peginterferon alfa-2a beyond
6 months post treatment.
A critical determinate of disease progression is the
development of cirrhosis from CHB. The general per-
ception of the clinical community seems to be that
HBeAg-negative disease is more likely to progress to
advanced liver disease than HBeAg-positive. For
example, the European Association for the Study of
the Liver consensus statement on hepatitis B estimated
that 2.0% to 5.5% of HBeAg-positive patients pro-
gress to cirrhosis per year compared to 8% to 10% of
HBeAg-negative patients [7]. Nevertheless, studies on
which these estimates are based are few and relatively
small, and patients who present with HBeAg-negative
disease are more likely to be older (and thus have more
advanced disease) [27–29]. We used 9% in our model
and varied it from 6% to 12% in a sensitivity analysis.
The remainder of the estimates for disease progression
(e.g., from cirrhosis) were assumed to be relatively
similar to those for HBeAg-positive disease
[21–24,30].
Quality of Life (Health State Utilities)
Estimates for the quality-of-life values (utilities) for
each of the health states in the model were derived
from previously published studies (Table 2). We
assumed the utility values for the HBV health states
were the same for HBeAg-positive and HBeAg-
negative disease. Pwu and Chan obtained utilities by
interviewing 12 Taiwanese hepatologists and 53
patients using the time trade-off technique (asking sub-
jects to trade years of life with a lower quality of life
for fewer years with a better quality of life) [23]. Based
on input from our survey of local hepatologists, we
chose to use a utility of 0.54 from a cost-effectiveness
analysis by Wong et al. rather than 0.65 from Pwu and
Chan, as the panel felt this value was more represen-
tative of the quality of life for patients in this health
state [22,23]. Wong et al. derived this estimate from
expert panel members who assessed their own utilities
for being in each CHB-related health state using 1) the
standard reference gamble (trading off years of future
healthy life to avoid immediate certain death), and 2)
the time trade-off technique, and taking an average of
these results. Because previous studies in HBV have
not estimated utilities for the liver transplantation
and post-liver transplantation health states, we used
values from a cost-effectiveness model of hepatitis C
treatment [31].
Health-Care Costs
The annual costs of CHB, compensated cirrhosis, and
decompensated cirrhosis were based on the average
level of medical resource utilization indicated from a
questionnaire survey among local hepatologists. Unit
costs from the Fee Schedule for Medical Service and
Reference List for Drugs set by the BNHI were used to
allocate costs to the medical resource use data [32].
The aggregated annual costs of managing these
disease states are shown in Table 3. A 25% increase
and decrease of the base-case cost for each disease state
was tested in sensitivity analyses. We assumed the costs
for the hepatitis B-related health states were the same
for HBeAg-positive and HBeAg-negative disease.
Table 2 Utility values for hepatitis B-related disease states
Disease state Utility value (low–high)
Combined response 1 (0.98–1) [23]
Chronic hepatitis B 0.95 (0.9–0.95) [23]
Compensated cirrhosis 0.9 (0.8–0.92) [23]
Decompensated cirrhosis 0.54 (0.5–0.65) [22]
Hepatocellular carcinoma 0.5 (0.3–0.5) [23]
Liver transplantation 0.5 (0.5–0.6) [31]
Post liver transplantation 0.7 (0.6–0.8) [31]
Table 3 Annual cost of managing chronic hepatitis B-related
complications
Disease state
Total annual management cost
per patient (low–high) (NTD)
Chronic hepatitis B 11,806 (8,855–14,758) [32]
Compensated cirrhosis 20,821 (15,616–26,026) [32]
Decompensated cirrhosis 44,431 (33,323–55,539) [32]
Hepatocellular carcinoma 96,510 (72,383–130,638) [33]
Liver transplantation 1,720,632 (1,290,474–2,150,790) [32,34]
Post liver transplantation 508,901 (381,676–636,126) [32]
NTD, New Taiwan Dollars.
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The total annual costs of managing CHB and
compensated cirrhosis were calculated based on the
resource utilization data of managing the disease after
drug therapy has been administered and has failed as
reported by the hepatologists in the survey. The annual
cost of managing decompensated cirrhosis was calcu-
lated by weighting the annual costs of diuretic-
sensitive ascites, refractory ascites, variceal
hemorrhage, and hepatic encephalopathy by the pro-
portion of patients in each of these disease states. The
proportion of patients with each complication in the
decompensated cirrhosis disease state was also deter-
mined from the survey (diuretic-sensitive ascites:
4.43%; refractory ascites: 6.17%; variceal hemor-
rhage: 1.36%; hepatic encephalopathy: 0.5%). The
cost for HCC was derived from a study by Wang on
the ﬁnancial burden of liver cancer in Taiwan [33].
Liver transplantation costs were estimated based on
the cost of a liver transplantation surgical procedure
and treatment costs to avoid infections [34]. Treatment
costs were based on the weekly BNHI price of
peginterferon alfa-2a 180 mg and lamivudine 100 mg
daily [32]. In the base case we assumed, all patients
received peginterferon alfa-2a 180 mg or lamivudine
100 mg for 48 weeks. Nevertheless, in the sensitivity
analysis, we adjusted the cumulative peginterferon
alfa-2a dose for 48 weeks treatment by approximately
10%, because the actual mean cumulative dose of
peginterferon alfa-2a used in the peginterferon alfa-2a
monotherapy arm of Marcellin et al.’s study [9] was
less than the per protocol cumulative dose because of
dose modiﬁcations.
Analysis Methods
The comparative performance of alternative treatment
strategies was depicted by the incremental cost-
effectiveness ratio (ICER) (deﬁned as the additional
cost of a speciﬁc strategy, i.e., peginterferon alfa-2a,
divided by its additional clinical beneﬁt, compared to
the next least expensive strategy, i.e., lamivudine)
[35–37]. All costs and outcomes were discounted at a
3% annual rate. One-way sensitivity analyses were
performed on all parameters in the model to identify
results drivers and evaluate uncertainty in the model.
In addition, although not requested by the Taiwan
BNHI or included in the formal submission, a proba-
bilistic sensitivity analysis was performed. Beta dis-
tributions were assigned to probability and utility
estimates, and normal distributions to cost estimates,
based on the parameter ranges listed in Tables 1–3.
Latin hypercube sampling was employed, and the con-
vergence criteria were set to a change of less than 1%
between successive simulations in the means and stan-
dard deviations of the model outcomes. The 95%
central range of values for the ICER was determined
and a cost-effectiveness acceptability curve generated.
Results
The main results of our analysis are shown in Table 4.
All costs are presented in NTD (1 USD = 31.96 NTD).
Treatment with peginterferon alfa-2a resulted in total,
discounted lifetime health-care costs associated with
HBeAg-negative CHB of 389,375 NTD compared to
232,382 NTD for lamivudine, for a difference of
156,992 NTD. Peginterferon alfa-2a drug therapy was
172,704 NTD more expensive than lamivudine, but
was offset by 15,711 NTD in savings of future medical
care cost for CHB. The discounted life-years gained in
the peginterferon alfa-2a arm was 11.45 years versus
11.07 years for lamivudine (a gain of 0.38). After
adjustment for quality of life in the various HBV-
related health states, peginterferon alfa-2a treatment
resulted in 10.57 QALYs and lamivudine 10.12
QALYs. The increase in quality-adjusted life expect-
ancy is 0.45 years with peginterferon alfa-2a at an
additional cost of 156,992 NTD per person compared
to lamivudine, yielding an ICER of 347,000 NTD
(10,900 USD) per QALY gained.
As shown in the one-way sensitivity analyses in
Figure 2, the ICER was most sensitive to variation in
the relapse rate after peginterferon alfa-2a treatment
was stopped, spontaneous relapse rate (relapse beyond
second year of post-treatment), the probability of
developing compensated cirrhosis from CHB, and the
relapse rate after lamivudine treatment was stopped.
Nevertheless, the ICER for peginterferon alfa-2a
compared to lamivudine monotherapy ranged from
281,000 to 448,000 NTD per QALY gained despite
independent variation in treatment efﬁcacy, the health
state transition probabilities, quality-of-life adjust-
ments, and health state cost estimates in one-way



















Peginterferon alfa-2a monotherapy (48 weeks) 389,375 15.32 11.45 10.57
Lamivudine monotherapy (48 weeks) 232,382 14.66 11.07 10.12
Difference 156,992 0.66 0.38 413,770 0.45 346,868
*The difference in cost divided by the difference in LY or QALY for each strategy compared to the next-best strategy.
LY, life-year; NTD, New Taiwan Dollars; QALY, quality-adjusted life-year.
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sensitivity analyses. A sensitivity analysis using the
costs derived from a claims database analysis by Hsieh
et al. increased the ICER to 361,000 NTD per QALY
gained from the base-case value of 347,000 NTD per
QALY gained [38]. The 95% central range from the
probabilistic sensitivity analysis for the discounted
incremental cost-utility ratio was 228,000–566,000
NTD (7100–17,700 USD). As shown in the cost-
effectiveness acceptability curve, for example, the
value placed on a QALY would have to be less than
350,000 NTD (11,100 USD) before the probability of
the intervention being cost-effective was below 50%
(Fig. 3).
Discussion
The results of our analysis suggest that peginterferon
alfa-2a therapy versus lamivudine treatment for
HBeAg-negative CHB in Taiwan provides incremental
beneﬁts in life expectancy and quality of life at an
increased total cost that is within the range of com-
monly reimbursed medical interventions [23,39]. In
the United States, 50,000 USD per QALY gained is
commonly used as the cutoff value for an ICER when
evaluating resource allocation, although this may
range up to 100,000 USD per QALY gained account-
ing for inﬂation and currently reimbursed health-care
interventions [37]. Although there is no consensus yet
on an ICER cutoff value in Taiwan, the annual income
per capita may serve as a guide. According to the
Department of Statistics, Ministry of Economic Affairs
in Taiwan, in 2003, GNP per capita was 13,156 USD
in Taiwan compared to 37,939 USD in the United
States. Therefore, an ICER of 17,300 USD per QALY
gained [(13,156/37,939) ¥ 50,000 USD], equivalent
to 553,000 NTD per QALY gained, is a potential
approximate threshold for Taiwan, although addi-
tional data on the cost-effectiveness of currently reim-
bursed health-care technologies are needed. Thus,
although reimbursement for peginterferon alfa-2a may
present a budgetary challenge, our analysis suggests
that such expenditure represents good value for
money. The clinical implications of our analysis are
also important. HBeAg-negative CHB is a difﬁcult-to-
treat disease, but because of the greater durable
response with peginterferon alfa-2a compared to lami-
vudine, our analysis suggests that peginterferon alfa-2a
offers signiﬁcantly improved long-term outcomes.
No other published studies to date have evaluated
the cost-effectiveness of peginterferon alfa-2a in the
treatment of HBeAg-negative CHB. In a recent study,
Kanwal et al. did evaluate the cost-effectiveness of
12 months of (nonpegylated) interferon alfa therapy
versus chronic antiviral (lamivudine or adefovir) treat-
ment for HBeAg-negative CHB [24]. The authors esti-
mated that interferon alfa was cost-effective compared
to lamivudine monotherapy, and in this regard the
ﬁndings, albeit of different treatments, are consistent
Figure 2 Results of one-way sensitivity analyses: 10 most inﬂuential
parameters. The width of the bars represents the high and low results
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Figure 3 Cost-effectiveness acceptability
curve.The curve represents the probability the
intervention is cost-effective over the range of
cost-effectiveness thresholds shown on the
x-axis.
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with ours. Kanwal et al. also reported that lamivudine
treatment followed by adefovir salvage led to the
greatest improvements in QALY. This ﬁnding is likely
to be a result of the durable treatment response used
for lamivudine-treated patients without resistance and
for adefovir-treated patients: 10% per year for the
duration of the simulation. As noted by the authors,
there are little data for these estimates, and further
clinical studies are needed.
Two previous studies have estimated the cost of
managing CHB and its complications in Taiwan: Pwu
and Chan in 2002 and Hsieh et al. in 2004 [23,38].
Pwu and Chan estimated costs from interviews with
Taiwanese hepatologists (apparently from academic
medical centers, as in our study) about common prac-
tice patterns for management of CHB, and from a
hospital medical chart review. Hsieh et al. estimated
costs based on the BNHI claims data from the year
2000. Of BNHI beneﬁciaries in Taiwan, 1% were ran-
domly selected and observed for 1 year. During this
1-year period, the relevant cost of medical care for
CHB or its complications (except liver transplantation)
was collected. The medical costs of CHB and compen-
sated cirrhosis in Hsieh et al.’s study are signiﬁcantly
lower than the costs used in our model and by Pwu and
Chan. We speculate that patients at academic medical
centers are more closely followed than patients in
Hsieh et al.’s study and provided with more intensive
medical care. The costs for decompensated cirrhosis
and HCC are more comparable between our model
and Hsieh et al.’s compared to that of Pwu and Chan.
Despite these different cost estimates, a sensitivity
analysis using the costs of Hsieh et al. increased the
ICER to only 361,000 NTD per QALY gained from
the base-case value of 348,000 NTD per QALY
gained.
There are several important limitations of this
study, primarily because of the paucity of long-term
treatment and disease progression data for HBeAg-
negative disease. In particular, the risk of progression
to cirrhosis for patients with chronic HBeAg-negative
HBV infection is not well understood. Nevertheless,
we varied this estimate between 6% and 12% without
a signiﬁcant change in our results. Treatment relapse
rates after the initial 6 months of follow-up were also
important parameters in the model; we varied these
from 15% to 35% for peginterferon alfa-2a and from
40% to 60% for lamivudine. Again, however, the
ICER remained less than NTD 450,000.
Several key assumptions in our study were conser-
vative, that is, favored lamivudine. We did not include
lamivudine drug resistance in the model. Although we
evaluated only 1 year of lamivudine treatment, resis-
tance in the pivotal clinical trial at 1 year was 17%;
patients experiencing resistance may have a higher
likelihood of disease progression, and increased
medical care costs, in part due to salvage treatment
with adefovir. We also assumed lamivudine-treated
patients continued to receive some, although diminish-
ing, beneﬁt once treatment was stopped. We did not
include HBsAg seroconversion, considered clinically to
be the closest to a “cure” in the model, although the
HBsAg seroconversion observed in the clinical trial
was 3% to 4% for peginterferon alfa-2a-treated
patients versus 0% for lamivudine-treated patients [9].
In summary, our analysis suggests that in HBeAg-
negative CHB, 48 weeks of treatment with peginter-
feron alfa-2a compared to 48 weeks of lamivudine
offers life expectancy and quality-of-life improvements
at a favorable cost-effectiveness ratio. Additional
studies evaluating the long-term disease and treatment
outcomes in HBeAg-negative CHB will be valuable for
assessing the clinical utility and economic value of
treatments for this challenging disease
Source of ﬁnancial support: Hoffman-La Roche.
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